Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), a global pharmaceutical company, announced the launch of Nerivio® Remote Electrical Neuromodulation (REN) wearable through its subsidiary betapharm. The launch in Germany marks Dr. Reddy’s entry into digital therapeutics in Europe.
Nerivio® is a United States Food and Drug Administration (USFDA) and CE-marked device for the prevention and treatment of migraine. The device, made by Theranica, a neuromodulation therapeutics company based in Israel and the USA, is the first REN wearable for acute and/or prevention migraine treatment for adults and adolescents (≥ 12 years).
The launch in Germany is the first step in Dr. Reddy’s plan to increase access to Nerivio® in European countries. The company plans to launch the device in Spain and the UK in the coming months.
According to Dr. Arne May, a leading researcher in the Department of Systems Neuroscience at the University of Hamburg, “Neuromodulation offers a significant advancement in migraine treatment. For decades, medication has been the mainstay of migraine management. However, many patients experience side effects or limited efficacy with these medications. Neuromodulation technologies offer a much-needed alternative. Such a modern neuromodulation technology is Nerivo®. By stimulating specific neural pathways, Nerivio can trigger the brain’s natural pain-relieving mechanisms, which were found to be deficient among migraine patients, without introducing chemical substances into the system. This drug-free approach holds particular promise for vulnerable populations such as adolescents and women of childbearing age, who may not be able to take conventional migraine medications.”
Patrick Aghanian, Chief Executive Officer of Dr. Reddy’s Europe, stated, “Starting with Germany, we are excited to introduce Nerivio® in Europe as a new drug-free innovation that can help migraine patients. Remote Electrical Neuromodulation (REN) has the potential to reduce the number of pills patients need to take and decrease their dependence on non-specific medication for chronic or hard-to-treat diseases. Worn on the upper arm and controlled by a smartphone app, makes it comfortable, discreet and portable. We believe that gives patients the freedom to focus on their daily activities while wearing it, addressing the unmet clinical need for more convenient migraine treatment, which significantly impacts well-being and quality of life.”
The prescribed Nerivio® REN wearable is indicated for acute and/or preventive treatment of migraine with or without aura in patients 12 years and older. Each device has the capability to provide 18 treatment sessions, each 45 minutes long. It is to be used within 60 minutes of the onset of headache or aura for acute treatment of migraine or every alternate day for prevention of migraine.
Multiple clinical trials have proven the efficacy of Nerivio® in providing relief from pain and associated migraine symptoms. It has also been shown to reduce the need for drugs used for abortive treatment. The device is suitable for a wide range of migraine patients, especially those who seek a drug-free therapy or have failed to control their migraine with medications. It is also well tolerated with no systemic side effects or concern for medication overuse.
In August 2023, Nerivio® received an expanded CE mark approval as a dual-use (acute and/or prevention) migraine treatment for adolescents and adults. The launch in Germany is the result of multiple exclusive agreements signed between Dr. Reddy’s European subsidiaries and Theranica for the commercial marketing and distribution of Nerivio® in several European countries, including Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland, and the United Kingdom.
The product has already been presented in Germany at the DGN Kongress 2023, organized by the German Association of Neurology in Berlin, following a successful launch in India in November 2023.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing affordable and innovative medicines. Driven by its purpose of ‘Good Health Can’t Wait’, the company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s major markets include the USA, India, Russia & CIS countries, China, Brazil, and Europe.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on
